SCHEMBL671450

SCHEMBL671450

COC(=O)C=Cc1ccc(OC)cc1C=O

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ERN1 O75460 1/20 0.54
TRIM24 O15164 1/20 0.54
TYR P14679 1/20 0.54
TRIM33 Q9UPN9 1/20 0.54
ALDH1A1 P00352 5/20 0.53
MAPT P10636 5/20 0.53
MEN1 O00255 2/20 0.53
KMT2A Q03164 2/20 0.53
JUN P05412 1/20 0.53
NFKB1 P19838 1/20 0.53
TDP1 Q9NUW8 1/20 0.50
LY96 Q9Y6Y9 1/20 0.49
ABCG2 Q9UNQ0 1/20 0.49
KDM4E B2RXH2 1/20 0.49
TP53 P04637 1/20 0.49
CYP1A2 P05177 1/20 0.49
CYP2C9 P11712 1/20 0.49
HPGD P15428 1/20 0.49
ALOX15 P16050 1/20 0.49
CYP2C19 P33261 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL671449 1.00 ERN1 (0.54) ERN1TRIM24TYRTRIM33ALDH1A1
SCHEMBL6170881 0.84 JUN (0.53) ALDH1A1MAPTMEN1KMT2AJUN
SCHEMBL6170877 0.84 JUN (0.53) ALDH1A1MAPTMEN1KMT2AJUN
SCHEMBL671461 0.83 ALDH1A1 (0.50) ERN1TYRALDH1A1MAPTMEN1
SCHEMBL671460 0.83 ALDH1A1 (0.50) ERN1TYRALDH1A1MAPTMEN1
SCHEMBL8685581 0.83 JUN (0.77) ALDH1A1MAPTMEN1KMT2AJUN
SCHEMBL3896958 0.83 MAPT (0.54) ALDH1A1MAPTMEN1KMT2AJUN
SCHEMBL31155862 0.83 MAPT (0.62) TRIM24TYRTRIM33ALDH1A1MAPT
SCHEMBL8685579 0.83 JUN (0.77) ALDH1A1MAPTMEN1KMT2AJUN
SCHEMBL7959387 0.83 MAPT (0.77) ALDH1A1MAPTMEN1KMT2AJUN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9422273-B2 Compounds act at multiple prostaglandin receptors giving a general anti-inflammatory response ALLERGAN, INC. (US) 2016-08-23 US disclosed
US-20160068520-A1 COMPOUNDS ACT AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE ALLERGAN, INC. 2016-03-10 US disclosed
US-9085567-B2 Compounds act at multiple prostaglandin receptors giving a general anti-inflammatory response ALLERGAN, INC. (US) 2015-07-21 US disclosed
US-20140249192-A1 COMPOUNDS ACT AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE ALLERGAN, INC. (US) 2014-09-04 US disclosed
EP-2606044-B1 COMPOUNDS ACT AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE ALLERGAN INC (US) 2014-06-04 EP disclosed
EP-2699565-A1 FATTY ACID AMIDE HYDROLASE INHIBITORS FOR TREATING PAIN Allergan, Inc. (US) 2014-02-26 EP disclosed
US-8653118-B2 Compounds act at multiple prostaglandin receptors giving a general anti-inflammatory response ALLERGAN, INC. (US) 2014-02-18 US disclosed
EP-2606044-A1 COMPOUNDS ACT AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE Allergan, Inc. (US) 2013-06-26 EP disclosed
US-20130150417-A1 COMPOUNDS ACT AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE ALLERGAN, INC. (US) 2013-06-13 US disclosed
WO-2012145737-A1 FATTY ACID AMIDE HYDROLASE INHIBITORS FOR TREATING ALLERGAN, INC. (US) 2012-10-26 WO disclosed
US-20120270915-A1 FATTY ACID AMIDE HYDROLASE INHIHIBITORS FOR TREATING PAIN ENERGY, UNITED STATES DEPARTMENT OF 2012-10-25 US disclosed
US-20120077858-A1 COMPOUNDS ACT AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE ALLERGAN, INC. (US) 2012-03-29 US disclosed
WO-2012024559-A1 COMPOUNDS ACT AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE ALLERGAN, INC. (US) 2012-02-23 WO disclosed
EP-0585371-B1 AROMATIC OLIGOMERIC COMPOUNDS USEFUL AS MIMICS OF BIOACTIVE MACROMOLECULES RHONE POULENC RORER INTERNAT H (US) 2002-04-17 EP disclosed
US-5571506-A AROMATIC ALDEHYDE OLIGOMERS FOR TREATMENT OF CARDIOVASCULAR DISORDERS, BONE METABOLISM, ANTILIPEMIC AGENTS AND GASTROINTESTINAL DISORDERS RHONE-POULENC RORER PHARMACEUTICALS INC. (US) 1996-11-05 US disclosed
EP-0585371-A4 AROMATIC OLIGOMERIC COMPOUNDS USEFUL AS MIMICS OF BIOACTIVE MACROMOLECULES RHONE POULENC RORER INT (US) 1994-07-13 EP disclosed
EP-0585371-A1 AROMATIC OLIGOMERIC COMPOUNDS USEFUL AS MIMICS OF BIOACTIVE MACROMOLECULES RHONE-POULENC RORER INTERNATIONAL (HOLDINGS) INC. (US) 1994-03-09 EP disclosed
WO-1992020350-A1 AROMATIC OLIGOMERIC COMPOUNDS USEFUL AS MIMICS OF BIOACTIVE MACROMOLECULES RHONE-POULENC RORER INTERNATIONAL (HOLDINGS) INC. (US) 1992-11-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120077858-A1 COMPOUNDS ACT AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE PTGER1, PTGER4, PTGER3 ERN1 894/4885TRIM24 3995/4885TYR 2112/4885
US-20120270915-A1 FATTY ACID AMIDE HYDROLASE INHIHIBITORS FOR TREATING PAIN FAAH, FAAH2, FAH ERN1 2862/4885TRIM24 1388/4885TYR 3548/4885
US-20130150417-A1 COMPOUNDS ACT AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE PTGER1, PTGER4, PTGER3 ERN1 1113/4885TRIM24 3352/4885TYR 1289/4885
US-20160068520-A1 COMPOUNDS ACT AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE PTGER1, PTGER4, PTGER3 ERN1 894/4885TRIM24 3995/4885TYR 2112/4885
US-20140249192-A1 COMPOUNDS ACT AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE PTGER1, PTGER4, PTGER3 ERN1 894/4885TRIM24 3995/4885TYR 2112/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.